Abbott Laboratories (NYSE:ABT) Stock Sale Revealed by Rep. Thomas H. Kean, Jr.

Key Points

• Rep. Thomas H. Kean Jr. sold Abbott Laboratories shares worth between $1,001 and $15,000 on September 17, with the transaction made through the Kean Family Partnership account.
• Abbott reported quarterly revenue of $13.01 billion, up 14.5% year over year, while adjusted earnings of $1.42 per share matched analyst estimates. The company also declared a quarterly dividend of $0.63, yielding approximately 2.3% annually.
• Wall Street maintains a “Moderate Buy” consensus on ABT, with an average price target of $118.32; the stock recently traded at $110.27, while institutional investors own about 75.18% of its shares.

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Abbott Laboratories NYSE: ABT. In a filing disclosed on October 30th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on September 17th. The trade occurred in the Representative's "KEAN FAMILY PARTNERSHIP" account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Stryker NYSE: SYK on 9/30/2026.
• Sold $1,001 - $15,000 in shares of Johnson & Johnson NYSE: JNJ on 9/30/2026.
• Purchased $1,001 - $15,000 in shares of ESAB NYSE: ESAB on 9/29/2026.
• Sold $1,001 - $15,000 in shares of Mondelez International NASDAQ: MDLZ on 9/23/2026.
• Purchased $1,001 - $15,000 in shares of Texas Instruments NASDAQ: TXN on 9/17/2026.
• Sold $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOGL on 8/27/2026.
• Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 8/27/2026.
• Sold $1,001 - $15,000 in shares of Johnson & Johnson NYSE: JNJ on 8/27/2026.
• Purchased $1,001 - $15,000 in shares of MasTec NYSE: MTZ on 8/21/2026.
• Sold $1,001 - $15,000 in shares of Amcor NYSE: AMCR on 8/10/2026.

Abbott Laboratories Stock Performance

NYSE ABT opened at $110.27 on Tuesday. The stock has a market cap of $190.80 billion, a price-to-earnings ratio of 19.08, a price-to-earnings-growth ratio of 1.80 and a beta of 0.59. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The business has a fifty day moving average of $104.23 and a 200-day moving average of $101.99. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $132.02.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, meeting analysts' consensus estimates of $1.42. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The business had revenue of $13.01 billion during the quarter, compared to the consensus estimate of $12.99 billion. During the same quarter in the previous year, the business earned $1.30 earnings per share. The business's revenue for the quarter was up 14.5% on a year-over-year basis. As a group, analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories's payout ratio is 94.03%.

Wall Street Analysts Forecast Growth

ABT has been the subject of a number of research analyst reports. Weiss Ratings raised shares of Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, September 18th. Barclays started coverage on shares of Abbott Laboratories in a report on Wednesday, October 7th. They set an "overweight" rating and a $120.00 target price on the stock. BTIG Research decreased their price target on shares of Abbott Laboratories from $134.00 to $125.00 and set a "buy" rating for the company in a research report on Thursday, October 22nd. Robert W. Baird increased their price target on Abbott Laboratories from $121.00 to $123.00 and gave the company an "outperform" rating in a report on Thursday, October 22nd. Finally, Wells Fargo & Company boosted their price objective on Abbott Laboratories from $112.00 to $119.00 and gave the stock an "overweight" rating in a research note on Thursday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $118.32.

Institutional Trading of Abbott Laboratories

A number of hedge funds have recently made changes to their positions in ABT. CenterBook Partners LP bought a new stake in shares of Abbott Laboratories during the 3rd quarter worth $633,000. Asset One Wealth Management LLC grew its position in Abbott Laboratories by 21.4% during the third quarter. Asset One Wealth Management LLC now owns 4,457 shares of the healthcare product maker's stock valued at $440,000 after acquiring an additional 787 shares during the last quarter. International Assets Investment Management LLC boosted its position in Abbott Laboratories by 6.0% during the third quarter. International Assets Investment Management LLC now owns 14,823 shares of the healthcare product maker's stock valued at $1,433,000 after buying an additional 839 shares during the period. Heritage Family Offices LLP bought a new position in Abbott Laboratories during the 3rd quarter worth approximately $216,000. Finally, Calamos Wealth Management LLC increased its stake in shares of Abbott Laboratories by 3.4% in the third quarter. Calamos Wealth Management LLC now owns 6,430 shares of the healthcare product maker's stock worth $635,000 after buying an additional 211 shares during the period. Hedge funds and other institutional investors own 75.18% of the company's stock.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey's 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey's 7th Congressional District. He declared candidacy for the 2026 election. Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women's health and cardiometabolic care.

The company's nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.